Biofluid Biomarker Discovery Solutions

Biomarkers are measurable molecular indicators that reflect physiological or pathological states (such as proteins, metabolites, and nucleic acids), providing critical scientific evidence for early disease diagnosis, treatment monitoring, and drug development. Biofluid biomarkers, owing to their noninvasive acquisition and capability for dynamic monitoring, have become a core tool in translational medicine:

1️⃣ Cerebrospinal Fluid (CSF): Directly captures intracerebral pathological changes associated with neurodegenerative diseases.

2️⃣ Blood (Serum/Plasma): Integrates systemic physiological signals, making it suitable for large-scale screening in cancers and cardiovascular diseases.

3️⃣ Saliva and Urine: With noninvasive sampling methods, these fluids support dynamic monitoring in pediatrics, infectious diseases, and chronic conditions.

 



Mansur, A. et al. Front Genet. 2024.

Figure 1. Commonly Used Biofluids and Biomarkers

 

However, accurately capturing disease-specific signals from biofluids still faces significant technical challenges. Many biofluid biomarkers with clinical potential are difficult to effectively detect and interpret due to their low abundance, complex post-translational modifications, and the lack of standardization arising from differences in sample processing.

 

MtoZ Biolabs offers a one-stop platform for biofluid biomarker discovery solutions—from discovery to clinical translation—based on mass spectrometry (MS) driven multidimensional omics analysis and a rigorously standardized workflow. Our comprehensive solutions cover the entire process of biofluid biomarker development. By employing multiple affinity chromatography combined with ultrafiltration techniques, we selectively remove serum albumin and immunoglobulins (removal rate >99%) to specifically enrich target biomarkers. Coupled with high-resolution Orbitrap mass spectrometry detection, our system achieves sensitivities down to the fg/mL level, effectively analyzing trace signals in samples. Furthermore, our customized enzymatic digestion and optimized mass spectrometry fragmentation strategies (such as HILIC glycopeptide retention and ETD fragmentation modes for phosphorylation) allow us to precisely identify modification types—including glycosylation and phosphorylation—and elucidate their biological functions.

 



Bao, Y. et al. Cancer Sci. 2024.

Figure 2. Comprehensive Workflow of Liquid Biopsy from Biofluid Collection to Clinical Application

 

Service Advantages

1. Ultra-Sensitive Detection  

• Applicability to Trace Samples: Ultra-deep proteomic analysis can be performed with as little as 100 μL of serum or CSF, addressing the challenge of limited volumes in precious clinical samples.  
• Precise Analysis of Complex Modifications: Phosphorylation site localization errors are less than one amino acid, and glycan composition can be determined covering over 20 types of monosaccharides.

 

2. Stringent Standardization Control  

Comprehensive SOP System: From sample collection and storage (transported on a -80°C cold chain) to analysis (mass spectrometry parameter calibration), we implement full-process quality control to support multi-center data integration.

 

3. Multi-Omics Driven Translational Research  

• Dual-Modality Validation Strategy: Combining DIA-MS for initial screening with PRM targeted validation ensures the reliability of the candidate biomarker list (with a false-positive rate below 1%).  
• Support for Dynamic Mechanism Studies: Time-series analyses in animal models (e.g., pre- and post-drug administration) reveal the dynamic changes of biomarkers during disease progression.

 

4. Rapid Delivery and Comprehensive Reporting  

• Efficient Project Cycle: Projects can be completed in a short timeframe, with the duration from sample receipt to data analysis determined based on project progress.  
• One-Stop Post-Project Support: We offer antibody development for candidate biomarkers and customization of ELISA kits, accelerating the translation of research findings.

 

Applications

1. Neurodegenerative Disease Research: Discovery of early diagnostic biomarkers and elucidation of drug action mechanisms.  

 

2. Precision Medicine in Cancer: Development of noninvasive liquid biopsy techniques through serum/saliva exosome proteomics analysis and studies on treatment resistance.  

 



Kumar, P. et al. Transl Oncol. 2024.

Figure 3. Potentials of Salivary Diagnostic Tests in Different Disease Diagnosis and Biomarker Discovery

 

3. Autoimmune and Inflammatory Diseases: Analysis of antibody modifications and biomarker stratification.

 

4. Infectious and Contagious Disease Research: Investigation of pathogen–host interaction mechanisms and evaluation of vaccine efficacy.

 

How Can We Help You?

1. Communication of Requirements: Fill out the inquiry form below to receive a customized solution.

   

2. Sample Submission: We support dry ice shipping and accept samples such as CSF (>100 μL), serum (>200 μL), and urine (>2 mL). For specific sample quantity requirements, please contact our technical staff.

   

3. Experiment and Analysis: Tailored analysis will be completed within 15 business days for routine projects, with real-time progress updates provided for complex projects.

   

4. Report Delivery: Reports include raw data, experimental methods and quality control documentation, biomarker identification and quantification results, advanced analysis and visualization, and both liquid chromatography and mass spectrometry data.

 

On your journey in biofluid biomarker discovery, MtoZ Biolabs is a partner you can trust! We break through the challenges of low-abundance targets with ultra-sensitive detection technology, overcome data comparability issues with our fully standardized workflows, and decode the mysteries of complex modifications through integrated multi-omics analysis. Contact us today for a free consultation and learn how we can support your research!